Aliskiren gained FDA approval for the treatment of hypertension in 2007. It is 
the first approved pharmaceutical to manage hypertension by direct renin 
inhibition. With the introduction of novel drugs and mechanisms of action comes 
the challenge of monitoring for new unreported adverse events. The side effect 
profile for aliskiren has not yet been fully described. We describe the first 
apparent report of aliskiren-induced QT prolongation resulting in torsades de 
pointes.